Shanzhou Duan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shanzhou Duan has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Yongbing Chen
Department of Thoracic Surgery, The Second Affiliated Hospital of Soochow University, Suzhou, China
6 shared publications - Lichen Yin
Soochow University
2 shared publications Qifeng Ding
2 shared publications- Wei Fang
Department of Pathology, People’s Hospital of Chizhou, Chizhou, China
2 shared publications - Xiaoxiao Dai
Department of Pathology, The Second Affiliated Hospital of Soochow University, Suzhou, China
2 shared publications - Yifei Wang
Department of Thoracic Surgery, The Second Affiliated Hospital of SoochowUniversity, Suzhou, China
2 shared publications
Latest Publications
- Open Access
- 26 September 2026
- Published by Springer Nature in Discover Oncology
- Vol. 17 (1) , 1378
Publisher Correction: MISP promotes the progression of lung adenocarcinoma through inhibition of the Hippo signaling pathway
- 26 September 2026
- Published by Springer Nature in Discover Oncology
- Vol. 17 (1) , 1378
Open AccessPublisher Correction: MISP promotes the progression of lung adenocarcinoma through inhibition of the Hippo signaling pathway
- Open Access
- 1 August 2026
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 18 (8) , 869
Comparison of Y20 with GEN11CN (Harmonic HD 1000i) ultrasonic energy device for sealing 5-7 mm pulmonary vessels in thoracoscopic surgery: a multicenter, randomized, assessor- and statistician-blinded, noninferiority trial
Background: Reliable sealing of 5–7 mm pulmonary vessels remains a persistent challenge in thoracoscopic surgery. Endostaplers are difficult to maneuver within the narrow interlobar fissure, and vascular clips are prone to slippage that can obscure the operative field. Ultrasonic energy devices offer an alternative for vessels of this caliber, but direct clinical comparisons between different device platforms are lacking. This study aimed to compare the success rate of sealing 5–7 mm blood vessels between a novel device (Y20) and the widely used GEN11CN (Harmonic HD 1000i). Methods: This was a multicenter, randomized, assessor- and statistician-blinded non-inferiority study. We enrolled patients aged 18–80 years scheduled for thoracoscopic anatomic segmentectomy or lobectomy who had at least one 5–7 mm vessel requiring sealing on computed tomography (CT) images, and randomly assigned them 1:1 to Y20 group or GEN11CN group. Patients with coagulopathy, severe thrombocytopenia, or recent active bleeding were excluded. Randomisation was stratified by centre using a central, computer-generated sequence held by an independent statistician. Device branding was masked with opaque covers so that the outcome evaluator remained blinded. The primary endpoint was the intraoperative vessel sealing success rate, defined as the absence of stump bleeding within a 10-minute observation window, with a prespecified non-inferiority margin of −10%. Secondary endpoints included intraoperative blood loss, operative time, postoperative drainage volume, and complications. Safety outcomes included laboratory parameters, vital signs, device-related sealing failures, and device-attributable complications. Results: Baseline characteristics were comparable except for higher systolic blood pressure (BP; 126.16 vs. 122.16 mmHg; P=0.02) and platelet count (221.07 vs. 200.73 ×109/L; P=0.03) in the Y20 group. Intraoperative vessel sealing success was achieved in 100.00% (90/90) of the experimental group and 98.88% (88/89) of the control group (P=0.30). The between-group difference was 1.12% [95% confidence interval (CI): −3.15% to 6.21%]. The lower limit of the 95% CI (−3.15%) was greater than the non-inferiority margin of −10% (P0.05). Device-related adverse events (AEs) occurred in 0/90 (0%) Y20 versus 1/89 (1.11%) GEN11CN patients. No serious device-related events, deaths, or postoperative hemorrhage occurred through 30 days. Conclusions: Y20 was noninferior to GEN11CN for intraoperative sealing of 5–7 mm pulmonary vessels and showed a comparable safety profile, supporting Y20 as a clinically acceptable alternative for this specific indication. These findings should not be generalized to vessels >7 mm or to settings without immediate rescue capability. Trial Registration: Chinese Clinical Trial Registry (ChiCTR2400088694; https://www.chictr.org.cn/showproj.html?proj=223068).
- 1 August 2026
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 18 (8) , 869
Open AccessComparison of Y20 with GEN11CN (Harmonic HD 1000i) ultrasonic energy device for sealing 5-7 mm pulmonary vessels in thoracoscopic surgery: a multicenter, randomized, assessor- and statistician-blinded, noninferiority trial
Background: Reliable sealing of 5–7 mm pulmonary vessels remains a persistent challenge in thoracoscopic surgery. Endostaplers are difficult to maneuver within the narrow interlobar fissure, and vascular clips are prone to slippage that can obscure the operative field. Ultrasonic energy devices offer an alternative for vessels of this caliber, but direct clinical comparisons between different device platforms are lacking. This study aimed to compare the success rate of sealing 5–7 mm blood vessels between a novel device (Y20) and the widely used GEN11CN (Harmonic HD 1000i). Methods: This was a multicenter, randomized, assessor- and statistician-blinded non-inferiority study. We enrolled patients aged 18–80 years scheduled for thoracoscopic anatomic segmentectomy or lobectomy who had at least one 5–7 mm vessel requiring sealing on computed tomography (CT) images, and randomly assigned them 1:1 to Y20 group or GEN11CN group. Patients with coagulopathy, severe thrombocytopenia, or recent active bleeding were excluded. Randomisation was stratified by centre using a central, computer-generated sequence held by an independent statistician. Device branding was masked with opaque covers so that the outcome evaluator remained blinded. The primary endpoint was the intraoperative vessel sealing success rate, defined as the absence of stump bleeding within a 10-minute observation window, with a prespecified non-inferiority margin of −10%. Secondary endpoints included intraoperative blood loss, operative time, postoperative drainage volume, and complications. Safety outcomes included laboratory parameters, vital signs, device-related sealing failures, and device-attributable complications. Results: Baseline characteristics were comparable except for higher systolic blood pressure (BP; 126.16 vs. 122.16 mmHg; P=0.02) and platelet count (221.07 vs. 200.73 ×109/L; P=0.03) in the Y20 group. Intraoperative vessel sealing success was achieved in 100.00% (90/90) of the experimental group and 98.88% (88/89) of the control group (P=0.30). The between-group difference was 1.12% [95% confidence interval (CI): −3.15% to 6.21%]. The lower limit of the 95% CI (−3.15%) was greater than the non-inferiority margin of −10% (P0.05). Device-related adverse events (AEs) occurred in 0/90 (0%) Y20 versus 1/89 (1.11%) GEN11CN patients. No serious device-related events, deaths, or postoperative hemorrhage occurred through 30 days. Conclusions: Y20 was noninferior to GEN11CN for intraoperative sealing of 5–7 mm pulmonary vessels and showed a comparable safety profile, supporting Y20 as a clinically acceptable alternative for this specific indication. These findings should not be generalized to vessels >7 mm or to settings without immediate rescue capability. Trial Registration: Chinese Clinical Trial Registry (ChiCTR2400088694; https://www.chictr.org.cn/showproj.html?proj=223068).
- Open Access
- 17 November 2025
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 2116
MISP promotes the progression of lung adenocarcinoma through Inhibition of the Hippo signaling pathway
Background Globally, lung cancer is a malignant tumor with the highest morbidity and mortality rate, of which lung adenocarcinoma (LUAD) is the most common pathological type, accounting for about 40% of all cases. This study aims to investigate the impact and molecular mechanisms of mitotic spindle positioning (MISP) on the occurrence and progression of LUAD. Methods The expression level of MISP were evaluated by qPCR and Western blotting. Hippo signaling-related protein levels were measured by Western blotting. Co-immunoprecipitation assay was applied to assess the interaction between MISP and MST1. The roles of MISP in LUAD cells were determined through CCK-8 assay, transwell migration/invasion assay, and flow cytometric analysis. A xenograft tumor model (n = 6) was established to calculate the effect of MISP in vivo. Results MISP expression was significantly higher in LUAD tissues compared to normal tissues. MISP overexpression promoted LUAD cell proliferation and migration in in vitro models, as well as tumor growth and metastasis in LUAD animal models. Western blotting demonstrated that MISP overexpression increased the expression of YAP, TAZ and CYR61, and decreased the expression of MST1 and phosphorylated YAP, thereby blocking the Hippo signaling pathway. While MISP knockdown had the opposite effect. Mechanistic experiments revealed that MISP directly interacts with MST1, thereby inhibiting Hippo signaling. Conclusions In conclusion, our study reveals a novel discovery that MISP promotes the growth and invasion of LUAD cells by interacting with MST1 and suppressing the Hippo pathway.
- 17 November 2025
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 2116
Open AccessMISP promotes the progression of lung adenocarcinoma through Inhibition of the Hippo signaling pathway
Background Globally, lung cancer is a malignant tumor with the highest morbidity and mortality rate, of which lung adenocarcinoma (LUAD) is the most common pathological type, accounting for about 40% of all cases. This study aims to investigate the impact and molecular mechanisms of mitotic spindle positioning (MISP) on the occurrence and progression of LUAD. Methods The expression level of MISP were evaluated by qPCR and Western blotting. Hippo signaling-related protein levels were measured by Western blotting. Co-immunoprecipitation assay was applied to assess the interaction between MISP and MST1. The roles of MISP in LUAD cells were determined through CCK-8 assay, transwell migration/invasion assay, and flow cytometric analysis. A xenograft tumor model (n = 6) was established to calculate the effect of MISP in vivo. Results MISP expression was significantly higher in LUAD tissues compared to normal tissues. MISP overexpression promoted LUAD cell proliferation and migration in in vitro models, as well as tumor growth and metastasis in LUAD animal models. Western blotting demonstrated that MISP overexpression increased the expression of YAP, TAZ and CYR61, and decreased the expression of MST1 and phosphorylated YAP, thereby blocking the Hippo signaling pathway. While MISP knockdown had the opposite effect. Mechanistic experiments revealed that MISP directly interacts with MST1, thereby inhibiting Hippo signaling. Conclusions In conclusion, our study reveals a novel discovery that MISP promotes the growth and invasion of LUAD cells by interacting with MST1 and suppressing the Hippo pathway.
- 7 March 2025
- Published by Elsevier in Acta Biomaterialia
- Vol. 196, 423-435
Oxygen/siRNA-carrying fluoro-nanosensitizers for radio-immunotherapy sensitization
- 7 March 2025
- Published by Elsevier in Acta Biomaterialia
- Vol. 196, 423-435
Oxygen/siRNA-carrying fluoro-nanosensitizers for radio-immunotherapy sensitization
- 24 February 2023
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 63 (3)
Clinical profiles and intraoperative identification of complex glands in stage I lung adenocarcinoma
This study aimed to investigate the potential of complex glandular patterns (CGP) in lymph node micrometastasis (LNMM), and to determine the clinical beneficiaries in stage I lung adenocarcinoma (LUAD) with CGP. Meanwhile, the feasibility of detecting CGP on frozen section was also evaluated. We retrospectively analyzed the clinicopathological characteristics of 848 pathologic-stage I LUADs. A logistic regression model and a Cox proportional-hazards model were conducted to define the risk factors for LNMM and survival respectively. Furthermore, five pathologists reviewed frozen sections of 100 LUADs independently. The logistic regression model indicated that CGP [odds ratio 3.89, 95% confidence interval (CI) 2.46–6.15; P < 0.001] was an independent predictor of the presence of LNMM. Subgroup analysis revealed that CGP-present/LNMM-positive LUAD had the highest risk of both loco-regional and distant recurrence. Moreover, adequate lymphadenectomy [recurrence-free survival: hazard ratio (HR) 0.61, 95% CI 0.40–0.95; P = 0.028; overall survival: HR 0.64, 95% CI 0.41–0.99; P = 0.043) and adjuvant chemotherapy (recurrence-free survival: HR 0.30, 95% CI 0.18–0.52; P < 0.001; overall survival: HR 0.33, 95% CI 0.19–0.57; P < 0.001) brought survival benefits to CGP-present patients, especially to CGP-present/LNMM-positive subgroup. Across the five pathologists, sensitivity ranged from 59% to 68% and specificity ranged from 79% to 83%, with moderate diagnostic agreement and high interobserver agreement for detecting CGP on frozen section. LNMM was more frequently observed in stage I LUAD with CGP. Adequate lymphadenectomy and adjuvant chemotherapy were associated with improved survival in CGP-present patients, especially in CGP-present/LNMM-positive subgroup. Additionally, it’s feasible to identify CGP on frozen section intraoperatively.
- 24 February 2023
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 63 (3)
Clinical profiles and intraoperative identification of complex glands in stage I lung adenocarcinoma
This study aimed to investigate the potential of complex glandular patterns (CGP) in lymph node micrometastasis (LNMM), and to determine the clinical beneficiaries in stage I lung adenocarcinoma (LUAD) with CGP. Meanwhile, the feasibility of detecting CGP on frozen section was also evaluated. We retrospectively analyzed the clinicopathological characteristics of 848 pathologic-stage I LUADs. A logistic regression model and a Cox proportional-hazards model were conducted to define the risk factors for LNMM and survival respectively. Furthermore, five pathologists reviewed frozen sections of 100 LUADs independently. The logistic regression model indicated that CGP [odds ratio 3.89, 95% confidence interval (CI) 2.46–6.15; P < 0.001] was an independent predictor of the presence of LNMM. Subgroup analysis revealed that CGP-present/LNMM-positive LUAD had the highest risk of both loco-regional and distant recurrence. Moreover, adequate lymphadenectomy [recurrence-free survival: hazard ratio (HR) 0.61, 95% CI 0.40–0.95; P = 0.028; overall survival: HR 0.64, 95% CI 0.41–0.99; P = 0.043) and adjuvant chemotherapy (recurrence-free survival: HR 0.30, 95% CI 0.18–0.52; P < 0.001; overall survival: HR 0.33, 95% CI 0.19–0.57; P < 0.001) brought survival benefits to CGP-present patients, especially to CGP-present/LNMM-positive subgroup. Across the five pathologists, sensitivity ranged from 59% to 68% and specificity ranged from 79% to 83%, with moderate diagnostic agreement and high interobserver agreement for detecting CGP on frozen section. LNMM was more frequently observed in stage I LUAD with CGP. Adequate lymphadenectomy and adjuvant chemotherapy were associated with improved survival in CGP-present patients, especially in CGP-present/LNMM-positive subgroup. Additionally, it’s feasible to identify CGP on frozen section intraoperatively.
- Open Access
- 1 February 2022
- Published by KEAI Publishing in Bioactive Materials
- Vol. 17, 320-333
Macrophage-targeting gene silencing orchestrates myocardial microenvironment remodeling toward the anti-inflammatory treatment of ischemia-reperfusion (IR) injury
Ischemia-reperfusion (IR) injury represents a major cause of myocardial dysfunction after infarction and thrombolytic therapy, and it is closely related to the free radical explosion and overwhelming inflammatory responses. Herein, macrophage-targeting nanocomplexes (NCs) are developed to mediate efficient co-delivery of siRNA against MOF (siMOF) and microRNA-21 (miR21) into myocardial macrophages, cooperatively orchestrating the myocardial microenvironment against IR injury. Bioreducible, branched poly(β-amino ester) (BPAE-SS) is designed to co-condense siMOF and miR21 into NCs in a multivalency-reinforced approach, and they are surface-decorated with carboxylated mannan (Man-COOH) to shield the positive surface charges and enhance the serum stability. The final MBSsm NCs are efficiently internalized by myocardial macrophages after systemic administration, wherein BPAE-SS is degraded into small segments by intracellular glutathione to promote the siMOF/miR21 release, finally provoking efficient gene silencing. Thus, cardiomyocyte protection and macrophage modulation are realized via the combined effects of ROS scavenging, inflammation inhibition, and autophagy attenuation, which ameliorates the myocardial microenvironment and restores the cardiac function via positive cellular crosstalk. This study renders promising solutions to address the multiple systemic barriers against in vivo nucleic acid delivery, and it also offers new options for IR injury by manipulating multiple reciprocal bio-reactions.
- 1 February 2022
- Published by KEAI Publishing in Bioactive Materials
- Vol. 17, 320-333
Open AccessMacrophage-targeting gene silencing orchestrates myocardial microenvironment remodeling toward the anti-inflammatory treatment of ischemia-reperfusion (IR) injury
Ischemia-reperfusion (IR) injury represents a major cause of myocardial dysfunction after infarction and thrombolytic therapy, and it is closely related to the free radical explosion and overwhelming inflammatory responses. Herein, macrophage-targeting nanocomplexes (NCs) are developed to mediate efficient co-delivery of siRNA against MOF (siMOF) and microRNA-21 (miR21) into myocardial macrophages, cooperatively orchestrating the myocardial microenvironment against IR injury. Bioreducible, branched poly(β-amino ester) (BPAE-SS) is designed to co-condense siMOF and miR21 into NCs in a multivalency-reinforced approach, and they are surface-decorated with carboxylated mannan (Man-COOH) to shield the positive surface charges and enhance the serum stability. The final MBSsm NCs are efficiently internalized by myocardial macrophages after systemic administration, wherein BPAE-SS is degraded into small segments by intracellular glutathione to promote the siMOF/miR21 release, finally provoking efficient gene silencing. Thus, cardiomyocyte protection and macrophage modulation are realized via the combined effects of ROS scavenging, inflammation inhibition, and autophagy attenuation, which ameliorates the myocardial microenvironment and restores the cardiac function via positive cellular crosstalk. This study renders promising solutions to address the multiple systemic barriers against in vivo nucleic acid delivery, and it also offers new options for IR injury by manipulating multiple reciprocal bio-reactions.
- Open Access
- 6 December 2018
- Published by Springer Nature in Cancer Cell International
- Vol. 18 (1) , 1-17
Prognostic impact of pretreatment lymphocyte-to-monocyte ratio in advanced epithelial cancers: a meta-analysis
There is increasing evidence that inflammation-based biomarkers are associated with tumor microenvironment which plays important roles in cancer progression. A high lymphocyte-to-monocyte ratio (LMR), has been suggested to indicate favorable prognoses in various epithelial cancers. We performed a meta-analysis to quantify the prognostic value of LMR in advanced-stage epithelial cancers undergoing various treatment. We searched PubMed, EMBASE, Web of science and Cochrane Library up to July 2018 for relevant studies. We included studies assessing the prognostic impact of pretreatment LMR on clinical outcomes in patients with advanced-stage epithelial cancers. The primary outcome was overall survival (OS) and the secondary outcome was progression free survival (PFS). The summary hazard ratio (HR) and 95% confidence interval (CI) were calculated. A total of 8984 patients from 35 studies were included. A high pretreatment LMR was associated with favorable OS (HR = 0.578, 95% CI 0.522–0.641, P < 0.001) and PFS (HR = 0.598, 95% CI 0.465–0.768, P < 0.001). The effect of LMR on OS was observed among various tumor types. A higher pretreatment LMR was associated with improved OS in chemotherapy (n = 10, HR = 0.592, 95% CI 0.518–0.676, P < 0.001), surgery (n = 10, HR = 0.683, 95% CI 0.579–0.807, P < 0.001) and combined therapy (n = 11, HR = 0.507, 95% CI 0.442–0.582, P < 0.001) in the subgroup analysis by different therapeutic strategies. The cut-off value for LMR was 3.0 (range = 2.35–5.46). Subgroup analysis according to the cut-off value showed a significant prognostic value of LMR on OS and PFS in both subgroups. A high pretreatment LMR is associated with favorable clinical outcomes in advanced-stage epithelial cancers undergoing different therapeutic strategies. LMR could be used to improve clinical decision-making regarding treatment in advanced epithelial cancers.
- 6 December 2018
- Published by Springer Nature in Cancer Cell International
- Vol. 18 (1) , 1-17
Open AccessPrognostic impact of pretreatment lymphocyte-to-monocyte ratio in advanced epithelial cancers: a meta-analysis
There is increasing evidence that inflammation-based biomarkers are associated with tumor microenvironment which plays important roles in cancer progression. A high lymphocyte-to-monocyte ratio (LMR), has been suggested to indicate favorable prognoses in various epithelial cancers. We performed a meta-analysis to quantify the prognostic value of LMR in advanced-stage epithelial cancers undergoing various treatment. We searched PubMed, EMBASE, Web of science and Cochrane Library up to July 2018 for relevant studies. We included studies assessing the prognostic impact of pretreatment LMR on clinical outcomes in patients with advanced-stage epithelial cancers. The primary outcome was overall survival (OS) and the secondary outcome was progression free survival (PFS). The summary hazard ratio (HR) and 95% confidence interval (CI) were calculated. A total of 8984 patients from 35 studies were included. A high pretreatment LMR was associated with favorable OS (HR = 0.578, 95% CI 0.522–0.641, P < 0.001) and PFS (HR = 0.598, 95% CI 0.465–0.768, P < 0.001). The effect of LMR on OS was observed among various tumor types. A higher pretreatment LMR was associated with improved OS in chemotherapy (n = 10, HR = 0.592, 95% CI 0.518–0.676, P < 0.001), surgery (n = 10, HR = 0.683, 95% CI 0.579–0.807, P < 0.001) and combined therapy (n = 11, HR = 0.507, 95% CI 0.442–0.582, P < 0.001) in the subgroup analysis by different therapeutic strategies. The cut-off value for LMR was 3.0 (range = 2.35–5.46). Subgroup analysis according to the cut-off value showed a significant prognostic value of LMR on OS and PFS in both subgroups. A high pretreatment LMR is associated with favorable clinical outcomes in advanced-stage epithelial cancers undergoing different therapeutic strategies. LMR could be used to improve clinical decision-making regarding treatment in advanced epithelial cancers.